Outlook on the Liquid Biopsy Global Market to 2026 - Key Drivers and Challenges

Dublin, Jan. 21, 2021 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Market Global Forecast by Cancer, Product, Sample, Circulating Biomarkers, Regions, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

This report provides a detailed analysis of Global Liquid Biopsy Industry. According to the research analysis, Global Liquid Biopsy Market is expected to be US$ 3.1 Billion by 2026.

A liquid biopsy is an emerging tool for the diagnosis of cancer disease nowadays. The liquid biopsy involves collecting samples and analysing tumours in the blood to diagnose cancer disease in the human body. Liquid biopsy assists medical practitioners as a source of genomic and proteomic knowledge in cancer patients by early detection of circulating tumour cells, DNA and extracellular vesicles. Currently, liquid biopsy plays a critical role in accelerating and implementing accurate oncology in clinical settings by leading to an improved understanding of tumour heterogeneity and allowing for dynamic control of reactions to care and variations in genomics.

The major growth drivers of liquid biopsies are that while extracting the tissue sample from the human body is much pain-free, it substitutes the pain associated with the procedure. Besides, liquid biopsy is very accurate in detecting tumour cells in the blood of cancer patients. Due to the low sensitivity of liquid biopsy, it acts as the restraint factor in the market's growth.

The key players play an essential role in the liquid biopsy market's growth by launching innovative products. In June 2020, NeoGenomics Inc. launched three liquid biopsy tests for non-small cell lung cancer, solid tumour types, and specific breast cancer. The COVID-19 effect in the liquid biopsy market has been harsh because all patients are taking therapies to treat cancer; since they have a weak immune system, and they are less prone to fight with coronavirus diseases.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Market Dynamics
3.1 Growth Drivers
3.2 Challenges

4. Global - Liquid Biopsy Market

5. Market Share - Global Liquid Biopsy
5.1 By Region
5.2 By Cancer
5.3 By Product
5.4 By Circulating Biomarkers

6. Region - Liquid Biopsy Market
6.1 North America
6.2 Europe
6.3 Asia-Pacific
6.4 Latin America
6.5 Middle East & Africa

7. Cancer - Liquid Biopsy Market
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Prostate Cancer
7.5 Others

8. By Product - Liquid Biopsy Market
8.1 Kits & Consumables
8.2 Instruments
8.3 Services

9. Circulating Biomarkers - Liquid Biopsy Market
9.1 Circulating Tumor cell (CTCs)
9.2 Circulating Tumor DNA (ctDNA)
9.3 Extracellular Vesicles (EVs)
9.4 Other Biomarkers (cell free DNA,etc)

10. By Clinical Application - Liquid Biopsy Market
10.1 Monitoring
10.2 Prognosis
10.3 Theranostics
10.4 Screening

11. By Sample - Liquid Biopsy Market
11.1 Plasma / Serum
11.2 Urine
11.3 Others

12. Company Analysis
12.1 Thermo Fisher Scientific Inc
12.1.1 Overview
12.1.2 Product Portfolio
12.2 Roche Diagnostics
12.2.1 Overview
12.2.2 Product Portfolio
12.2.3 Financial Insight
12.3 Bio-Rad Laboratories Inc
12.3.1 Overview
12.3.2 Product Portfolio
12.3.3 Financial Insight
12.4 Biocept, Inc.
12.4.1 Overview
12.4.2 Product Portfolio
12.5 Biocartis
12.5.1 Overview
12.5.2 Product Portfolio
12.5.3 Financial Insight
12.6 Myriad Genetics, Inc
12.6.1 Overview
12.6.2 Product Portfolio
12.6.3 Financial Insight
12.7 Genomic Health
12.7.1 Product Portfolio
12.7.2 Financial Insight
12.8 NeoGenomics Laboratories
12.8.1 Overview
12.8.2 Product Portfolio
12.8.3 Financial Insight
12.9 Qiagen
12.9.1 Overview
12.9.2 Product Portfolio
12.9.3 Financial Insight

For more information about this report visit https://www.researchandmarkets.com/r/hd7m30

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900